Table 6 Baseline characteristics of patients with biologic naïve or not.
From: Real-world retention rates of biologics in patients with rheumatoid arthritis
TNF inhibitor | Naïve | Second or later | p-value |
|---|---|---|---|
Cases (no.) | 325 | 128 | |
Age (years) | 58.8 ± 15.3 | 62.0 ± 14.5 | 0.0423 |
Male rate (%) | 20.9 | 17.2 | 0.4331 |
Body weight (kg) | 54.9 ± 11.4 | 55.3 ± 13.8 | 0.7427 |
BMI | 22.1 ± 3.5 | 22.5 ± 4.4 | 0.3647 |
ACPA positivity (%) | 87.2 | 92.2 | 0.1866 |
RF positivity (%) | 78.6 | 85.2 | 0.1467 |
MMP3 (ng/ml) | 267.8 ± 251.0 | 241.1 ± 268.3 | 0.3237 |
PSL usage (%) | 62.3 | 64.8 | 0.6649 |
MTX usage (%) | 82 | 79.7 | 0.5928 |
PSL dose (mg/day) | 5.4 ± 2.8 | 4.8 ± 2.4 | 0.0274 |
MTX dose (mg/week) | 7.6 ± 2.9 | 7.6 ± 3.9 | 0.5924 |
